PUBLISHER: DataM Intelligence | PRODUCT CODE: 1138278
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1138278
Veno-Venous Extracorporeal Life Support (VV ECLS) Devices Market is expected to grow at a high CAGR of 9.4% during the forecasting period (2022-2029).
Extracorporeal life support (ECLS), also known as extracorporeal membrane oxygenation (ECMO), is an extracorporeal technique that provides prolonged cardiac and respiratory support to the heart and lungs which are not able to provide an adequate amount of gas exchange or perfusion to sustain life. The technology for ECLS is derived from cardiopulmonary bypass, which provides shorter-term support with arrested native circulation.
In venovenous (VV) ECLS, cannulae are placed in the right common femoral vein for drainage and the right internal jugular vein for infusion. Alternatively, a dual-lumen catheter is inserted into the right internal jugular vein, draining blood from the superior and inferior vena cavae and returning it to the right atrium.
The global veno-venous extracorporeal life support (VV ECLS) devices market is growing due to several driving factors such as increasing the prevalence of cardiopulmonary disease & respiratory disorders and, raising awareness of the cardiopulmonary disease and increasing demand for cardiopulmonary monitoring and treatment system.
The increasing prevalence of cardiopulmonary disease & respiratory disorders is propelling the global market growth.
Cardiopulmonary disease refers to a range of diseases that affect the heart and the lungs, there are two common types of cardiopulmonary conditions: cardiovascular disease; and chronic obstructive pulmonary disorder (COPD), and their growing prevalence is driving the global market growth. For instance, according to the British Heart Foundation, around 168,319 people died from CVD in 2020. Cardiopulmonary diseases are rising due to several factors, such as the growing geriatric population, rising disposable income, changing lifestyles, smoking, and others; for instance, according to the world health organization, in 2020, there were 1 billion people aged 60 and above in 2020 and is estimated that by 2050 it will reach 2.1 billion. However, tobacco consumption is the cause behind over 8 million deaths each year globally, of which 7 million are due to direct use, and 1.2 million are because of non-smokers exposed to secondhand smoke. The Venovenous extracorporeal life support (VV ECLS) devices help the patients maintain the body to a normal level through appropriate intervention. These devices have shown favorable neonatal results and help maintain acute respiratory distress syndrome (ARDS) and single-ventricle physiology. As of April 2022, 172,853 patients had been placed on extracorporeal life support (ECLS) internationally, of which 46,698 were neonates, 93,091 were adults, and 33,064 were older children. The number of registered ELSO centers and their yearly use of ECLS increased precipitously in the last few years to 543 centers in 2021 and 17777 runs in 2021, respectively.
The complications and lack of skilled professionals hinder the global Veno-venous extracorporeal life support (VV ECLS) device market growth.
However, several complications associated with extracorporeal life support devices, such as bleeding, infections, and technical failures, coupled with the high cost of the devices and lack of skilled professionals, hinder the market's growth.
As COVID-19 is a severe acute respiratory syndrome that causes difficulty in breathing, and since extracorporeal membrane oxygenation (ECMO) is an extracorporeal technique that provides prolonged respiratory support to the lungs, the outburst of COVID-19 caused a rise in the demand for the extracorporeal membrane oxygenation (ECMO) therefore positively impacting the global market growth. For instance, according to the Extracorporeal Life Support Organization, 13988 Confirmed COVID-19 patients initiated ECMO at least 90 days ago.
Veno-venous extracorporeal life support (VV ECLS) devices are predicted to have a high demand during the forecast period (2022-2029).
The veno-venous extracorporeal life support (VV ECLS) devices market is segmented into the hindergle-ventricular device and biventricular device by product type. Among these, the venovenous extracorporeal life support (VV ECLS) devices in single-ventricle patients have shown increased market share in 2021 and are estimated to grow significantly over the forecast period. Single-site dual-lumen cannulas are used in infants, children, and adults. This approach incorporates drainage and reinfusion lumens into one unit inserted through the right internal jugular vein (RIJV). However, the venovenous ECLS has a substantial risk in patients with single-ventricle disorder due to coronary, pulmonary, and cerebral circulations. Biventricular devices supported with a paracorporeal pulsatile device are an efficient bridge to recovery for patients with fulminant myocarditis-related cardiogenic shock.
North America is predicted to command the global Veno-venous Extracorporeal Life Support (VV ECLS) Devices market.
North America is dominating the global veno-venous extracorporeal life support (VV ECLS) devices market, accounting for the largest market share in 2021, owing to the rising prevalence of cardiopulmonary diseases, growing aging population, and active intervention by the government like the "Million Hearts" initiative by U.S. government to spread awareness about risk associated with cardiopulmonary diseases. According to the CDC, every 34 seconds, a U.S. American dies because of cardiovascular disease; in 2020, 697,000 American deaths were caused by cardiovascular disease. The North American VV ECLS market is expected to grow rapidly over the forecast period, owing to the rising demand for new innovative products. Terumo Cardiovascular Systems Corporation has refined existing technology while manufacturing CAPIOX FX Oxygenator.
The veno-venous extracorporeal life support (VV ECLS) devices market is competitive with few major players. Some of the major players in the global veno-venous extracorporeal life support (VV ECLS) devices market include Medtronic, Plc, MAQUET Holding B. V. & Co. KG (Getinge Group), Microport Scientific Corporation, Sorin Group, Nipro Medical Corporation, Terumo Cardiovascular Systems Corporation, MedosMedizintechnik AG, among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations contributing to the veno-venous extracorporeal life support (VV ECLS) devices market globally. For instance, on July 12, 2022, Medtronic announced a co-promotion agreement with CathWorks, with an acquisition plan. Also, on 02 Jun 2022, Hemovent achieved MDSAP Certificate for the United States and Canada.
Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.
The product portfolio of Medtronic, Plc. The product portfolio for veno-venous extracorporeal life support (VV ECLS) devices contains Nautilus Smart ECMO Module, Nautilus ECMO Oxygenator, Crescent RA Jugular Dual Lumen Catheter and Crescent Jugular Dual Lumen Catheter.
The global veno-venous extracorporeal life support (VV ECLS) devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
LIST NOT EXHAUSTIVE